key: cord-0714054-hc0yj65p
authors: Lee, J.; Kim, J. H.; Liu, C.; Hripcsak, G.; Ta, C.; Weng, C.
title: COHD-COVID: Columbia Open Health Data for COVID-19 Research
date: 2020-11-18
journal: nan
DOI: 10.1101/2020.11.17.20232983
sha: 0ed4fcaf460bdba3b9dbbbc243f8355ca3da5149
doc_id: 714054
cord_uid: hc0yj65p

Massive research efforts have been made in response to the COVID-19 (coronavirus disease-2019) pandemic. Utilization of clinical data can accelerate these research efforts to fight against the pandemic since important characteristics of the patients are often found by examining the clinical data. To provide shareable clinical data to catalyze COVID-19 research, we present Columbia Open Health Data for COVID-19 Research (COHD-COVID), a publicly accessible database providing clinical concept prevalence, clinical concept co-occurrence, and clinical symptom prevalence for hospitalized COVID-19 patients. COHD-COVID also provides data on hospitalized influenza patients and general hospitalized patients as comparator cohorts. The data used in COHD-COVID were obtained from Columbia University Irving Medical Center's electronic health records. We expect COHD-COVID will provide researchers and clinicians quantitative measures of COVID-19 related clinical features to better understand and fight against the pandemic.

depicts the overall workflow to create COHD-COVID. Columbia's clinical data warehouse has been converted to the OMOP CDM on a regular basis. We first filtered the EHR data according to the cohort definitions, then EHR for each patient's inpatient visits were identified. Condition, drug, and procedure concepts were obtained from the identified visits. Concept prevalence, concept prevalence ratio, concept co-occurrence, and symptom prevalence analyses were followed using the obtained concepts. To protect patient privacy, we excluded rare concepts observed in 10 or fewer visits and perturbed the true counts using Poisson randomization. Perturbed counts generated by the Poisson randomization process do not show statistically significant difference from the true counts 9 . The resulting data were stored in a MySQL database and made publicly available via a web API (http://covid.cohd.io/).

We utilized EHR data from the CUIMC's clinical data warehouse, where inpatient and outpatient data dating back to 1985 are stored. CUIMC has converted its clinical data warehouse to OMOP CDM on a regular basis. Since CUIMC covers New York City and the surrounding area, which has a diverse population of 8.2M people and was an early COVID-19 epicenter, the EHR data from CUIMC can provide a diverse and large sample of COVID-19 patients.

Three different patient cohorts were used in this study. The COVID-19 cohort was defined as hospitalized patients aged 18 or older with a COVID-19 related condition diagnosis and/or a confirmed positive COVID-19 test during their hospitalization period or within the prior 21 days. Patients identified with the COVID-19 cohort definition from March 1, 2020 to September 1, 2020 were used for the COVID-19 cohort. The influenza cohort was similarly defined as patients aged 18 or older who had at least one occurrence of influenza conditions or pre-coordinated positive measurements or positive influenza testing in the prior 21 days or during their hospitalization period. The general cohort was defined as all hospitalized patients aged 18 or older. Patient visits from calendar years 2014 to 2019 were included for the influenza and general cohorts. The COVID-19 cohort was divided into sub-cohorts stratified by sex (male vs. female) and age (adult vs. senior (65+)) for further investigation. The COVID-19 and influenza cohort definitions were adapted from the cohort definitions created by the Observational Health Data Science and Informatics' (OHDSI) international network study for COVID-19 3 .

Patients belonging to the cohorts based on the three cohort definitions above were identified using the unique person_id from the person table in the OMOP CDM. Condition, drug, and procedure concepts observed in these patients during inpatient visits were extracted from the condition_occurrence, drug_exposure, and procedure_occurrence tables in the OMOP CDM, respectively. Inpatient visits of patients and the concepts in these visits were identified using visit_occurrence_id and person_id, along with the visit_concept_id from the visit_occurrence table. We used visit-based count instead of patient-based count in the following analyses for robust comparison between cohorts lie in different observation window. For example, if we use patientbased count, the patients included in cohorts with longer observation window are likely to have more concepts than the patients in cohorts with shorter observation window, which could inject bias into the metrics used in the analyses. Thus, we used visit-based count that cannot be affected by the length of observation window to reduce the bias.

We calculated the concept prevalence in each cohort as detected from the EHR. The concept prevalence is defined as Eq(1):

where is the prevalence of concept C in cohort H, is the set of unique inpatient visits of patients in cohort H observed with concept C, and is the set of unique inpatient visits of patients in cohort H. We also calculated hierarchical concept prevalence by defining as the set of unique visits of patients observed with concept C or any of concept C's descendant concepts as defined in the concept_ancestor table in the OMOP CDM. For example, the hierarchical count for Ibuprofen (OMOP concept ID 1177480) not only includes entries where the specific concept Ibuprofen was used, but also includes entries using other descendant concepts, such as Ibuprofen 600 MG Oral Tablet (OMOP concept ID 19019073). Taking hierarchical relationships into account mitigates some of the issues with coding variations across time and practices as different concepts with minor semantic differences can be aggregated into higher-level concepts.

The concept prevalence ratio indicates how frequently concept C occurs in cohort A relative to cohort B. The natural logarithm of the concept prevalence ratio is defined as Eq (2):

where ( , ) is the log ratio of the prevalence of concept C for cohort A to cohort B, is prevalence of concept C in cohort A, and is prevalence of concept C in cohort B. Hierarchical concept prevalence ratio can be calculated by using hierarchical concept prevalence and .

Concept co-occurrence represents how frequently a specific concept pair appears in a cohort. We defined concept co-occurrence prevalence as Eq (3):

where , is the co-occurrence prevalence of concepts and in cohort H, , is the set of unique visits of patients observed with concept and in cohort H, and is the set of unique visits of patients in the cohort H. We also calculated hierarchical concept co-occurrence using the hierarchy of concepts as described above.

Since clinical symptoms often include multiple granular clinical concepts, a set of related concepts for a symptom is required to calculate the prevalence of the symptom. For example, dyspnea, which is one of the major symptoms of COVID-19, can be detected as standard concept Dyspnea or Acute respiratory distress in different patients. The two concepts do not have any hierarchical relationship and thus will not be aggregated by the hierarchical prevalence analyses. Thus, a concept set containing both Dyspnea and Acute respiratory distress is needed for accurate calculation of the prevalence of cough symptom. We defined symptom prevalence as Eq(4):

where is prevalence of symptom S in cohort H, is the set of unique visits of patients observed with concept , is the set of unique visits of patients observed in the cohort H, and s is the number of the unique concepts in the concept set for symptom S. Hierarchy between concepts is not considered in the symptom prevalence analysis since a concept set of a symptom already reflects hierarchy for that symptom.

We used concept sets for 11 major symptoms of COVID-19 (Cough, Chills, Abdominal pain, Diarrhea, Dyspnea, Fatigue, Fever, Myalgia, Nausea and vomiting, Tachypnea, and Throat pain) that have been defined by OHDSI to calculate symptom prevalence. The concepts included in each symptom are available in figshare 13 .

The results of all analyses, concept definitions, and concepts included in each symptom are available as tab-delimited flat files in figshare 13 . The results of the concept prevalence ratio analysis were not included in the record since they can be directly computed from concept prevalence available in the record. The COHD-COVID API (http://covid.cohd.io/) provides the results of concept prevalence and concept co-occurrence analyses. The prevalence and cooccurrence are relative to a maximum of 1.0 (1.0 = 100%) and all concepts are referenced by their OMOP standard concept ID. Brief descriptions for the flat files are: covid_full_(non)hierarchical_concept_prevalence.txt: Hierarchical and non-hierarchical concept prevalence for the full COVID-19 cohort. The columns are OMOP concept ID, count of patients' visits with the concept, and prevalence of patients' visits with the concept. Concept prevalence for all sub-cohorts of the COVID-19 cohort are also available using the same file structure and with the sub-cohort name indicated in the filename (i.e., covid_[adult|senior|male|female]_(non)hierarchical_concept_prevalence.txt.) covid_full_(non)hierarchical_concept_cooccurrence.txt: Hierarchical and non-hierarchical concept co-occurrence prevalence for the full COVID-19 cohort. The columns are the first OMOP concept ID, second OMOP concept ID, count of patients' visits with the concept pair, and . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ;  prevalence of patients' visits with the pair of concepts. Concept co-occurrence prevalence for all sub-cohorts of the COVID-19 cohort are also available using the same file structure and with the sub-cohort name indicated in the filename (i.e., covid_[adult|senior|male|female]_(non)hierarchical _concept_cooccurrence.txt).

covid_full_symptom_prevalence.txt: Symptom prevalence for the full COVID-19 cohort. The columns are symptom name, the number of unique concepts having nonzero count in the symptom, count of patients' visits with the symptom, and prevalence of patients' visits with the symptom. Symptom prevalence for all sub-cohorts of the COVID-19 cohort are also available (i.e., covid_[adult|senior|male|female]_symptom_prevalence.txt).

covid_epic_shift_pvalue.txt: p-values of t-tests between counts from pre-Epic switch period and post-Epic switch period for all concepts in the full COVID-19 cohort. The columns are OMOP concept ID and p-value of the t-test for the concept. These are results from part of the data quality analysis in the following section.

influenza_(non)hierarchical_concept_prevalence.txt: Hierarchical and non-hierarchical concept prevalence for the influenza cohort. The columns are OMOP concept ID, count of patients' visits with the concept, and prevalence of patients' visits with the concept.

influenza_(non)hierarchical_concept_cooccurrence.txt: Hierarchical and non-hierarchical cooccurrence prevalence for the influenza cohort. The columns are the first OMOP concept ID, second OMOP concept ID, count of patients' visits with the concept pair, and prevalence of patients' visits with the pair of concepts.

influenza_symptom_prevalence.txt: Symptom prevalence for the influenza cohort. The columns are symptom name, the number of unique concepts having nonzero count in the symptom, count of patients' visits with the symptom, and prevalence of patients' visits with the symptom.

influenza_concept_prevalence_yearly_deviations.txt: The means and standard deviations of concept prevalence calculated based on the annual prevalence from the influenza cohort. The columns are OMOP concept ID, mean annual prevalence of the concept, and standard deviation of the annual prevalence of the concept.

influenza_concept_cooccurrence_yearly_deviations.txt: The means and standard deviations of concept co-occurrence prevalence calculated based on the annual prevalence from the influenza cohort. The columns are the first OMOP concept ID, second OMOP concept ID, mean annual cooccurrence prevalence of the concept pair, and standard deviation of the annual co-occurrence prevalence of the concept pair. general_(non)hierarchical_concept_prevalence.txt: Hierarchical and non-hierarchical concept prevalence for the general cohort. The columns are OMOP concept ID, count of patients' visits with the concept, and prevalence of patients' visits with the concept. general_(non)hierarchical_concept_cooccurrence.txt: Hierarchical and non-hierarchical cooccurrence prevalence for the general cohort. The columns are the first OMOP concept ID, second . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint OMOP concept ID, count of patients' visits with the concept pair, and prevalence of patients' visits with the pair of concepts.

general_symptom_prevalence.txt: Symptom prevalence for the general cohort. The columns are symptom name, the number of unique concepts having nonzero count in the symptom, count of patients' visits with the symptom, and prevalence of patients' visits with the symptom.

general_concept_prevalence_deviations.txt: The means and standard deviations of concept prevalence calculated based on the annual prevalence from the general cohort data. The columns are OMOP concept ID, mean annual prevalence of the concept, and standard deviation of the annual prevalence of the concept.

general_concept_cooccurrence_deviations.txt: The means and standard deviations of concept co-occurrence calculated based on the annual prevalence from the general cohort data. The columns are the first OMOP concept ID, second OMOP concept ID, mean annual co-occurrence prevalence of the concept pair, and standard deviation of the annual co-occurrence prevalence of the concept pair.

concepts.txt: The definitions for all concepts used in the analyses. The columns are OMOP concept ID, concept name, domain, source vocabulary (the vocabulary that originally defined the concept, e.g., SNOMED, RxNorm, etc.), and concept class.

symptoms.txt: The definitions for all symptoms used in the symptom prevalence analysis. The columns are the symptom, OMOP concept ID, concept name, and domain.

We analyzed CUIMC's EHR data by calculating concept prevalence, concept prevalence ratio, concept co-occurrence, and symptom prevalence for three different cohorts, including the COVID-19 cohort. Summary statistics of the cohorts are provided in Table 1 .

Concept prevalence and concept co-occurrence analysis on the COVID-19 cohort contain 1,066 concepts and 49,666 concept pairs, respectively, covering 290 condition, 705 drug, and 71 procedure concepts. Concept prevalence and concept co-occurrence analysis on the influenza cohort contain 1,392 concepts and 58,469 concept pairs, respectively, covering 510 condition, 756 drug, and 126 procedure concepts. Concept prevalence and concept co-occurrence analysis on the general cohort contain 11,250 concepts and 1,297,928 concept pairs, respectively, covering 4,362 condition, 3,428 drug, and 3,460 procedure concepts. Descriptive statistics of the results from the two analyses for each cohort are summarized in Table 2 and 3. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint

Assessing data quality of EHR data is critical for its effects on secondary analysis for research in the healthcare and medical domains 14 . We calculated the sum of non-randomized counts of all concepts on a monthly basis for the COVID-19 cohort and on a yearly basis for the general and influenza cohorts. For each of the condition, drug, and procedure domains, we examined the total counts of concepts with the number of visits to detect any issues regarding data quality and temporal plausibility of the EHR data we used in the study 15 . A change in the EHR system can affect the quality and characteristics of EHR data collected for secondary research. CUIMC changed its EHR system as of February 1 st , 2020 from Allscripts to Epic, which might affect the COVID-19 cohort data and its characteristics as compared against the influenza and general cohorts, which were collected prior to the EHR change. To detect the impact of the change, we performed a t-test for all concepts reported in the COVID-19 cohort between the counts from a pre-Epic period (January 1, 2020 -January 31, 2020) and from a post-Epic period (February 1, 2020 -Feb 29, 2020). The post-Epic period was chosen to minimize the inclusion of dates when COVID-19 would have impacted clinical practices in NYC. The counts of concepts were recorded on a daily basis. We considered there to be no difference between the two periods if the counts for the concept from the two periods are the same (i.e. all 0 counts for the two periods). Of all 1,066 unique concepts reported in the COVID-19 cohort, 119 (11.2%) concepts show a statistically meaningful difference (p-value ≤ 0.01) between the pre-and post-Epic periods. The p-values of the t-tests for all individual concepts are available in figshare 13 to allow users to factor in these data quality considerations for each concept. The annual mean and standard deviation of concept prevalence and concept co-occurrence for the general and influenza cohorts are available in figshare 13 to assess the temporal variance of each concept and concept-pair. The mean and standard deviation of annual concept prevalence and cooccurrence should only be compared to each other to assess stability of the concept over the given time period of the dataset.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 18, 2020. ;

In this section, we show several motivating use cases to demonstrate the utility of COHD-COVID.

Concept prevalence analysis on the three cohorts can be used to find clinical characteristics of the COVID-19 cohort. Figure 4 shows the prevalence of 10 (a) condition and (b) drug concepts in the COVID-19 cohort, influenza cohort, and general cohort. We chose the 10 most prevalent condition and drug concepts in the COVID-19 cohort for this use case. For drug concepts, we chose the most prevalent drug ingredient concepts using hierarchical analysis to count multiple drugs having different brand names, dosages, and formulations but based on the same ingredients together. The condition concepts were chosen without hierarchical analysis to identify the top 10 specific conditions. Comparing the prevalence of these concepts between the COVID-19 cohort and the influenza or general cohorts provides contexual clues whether the concept is associated with COVID-19 or if its common among hospitalized patients. From Figure 4 (a), we can confirm that Fever, Cough, Dyspnea, and Acute lower respiratory syndrome were more highly prevalent in the COVID-19 cohort than the two comparator cohorts. Acetaminophen was the most prevalent drug ingredient used for COVID-19 patients, which aligns with the high prevalence of Fever. We can see that Hydroxychloriquine, which was one of the drugs widely administered to COVID-19 patients 17 , showed high prevalence in the COVID-19 cohort.

Concept prevalence analysis on the COVID-19 cohort and its sub-cohorts can be used to find clinical characteristics of the sub-cohorts. Figures 5 and 6 show the prevalence of 10 (a) condition and (b) drug concepts, respectively, in the COVID-19 cohort stratified by gender and age. The 10 condition and drug concepts were the top 10 most prevalent concepts in the full COVID-19 cohort without stratification (the same concepts and prevalence calculation methods as in Use Case 1). Figure 5 (a) shows that the senior cohort had higher prevalences in all 10 condition concepts than the full and adult cohorts. We can also confirm that Essential hypertension and Hypoxemia were particularly more prevalent in senior COVID-19 patients.

Concept prevalence ratio analysis can be used to unveil how often specific concepts appeared in the COVID-19 cohort compared to the comparator cohorts. For example, Table 4 shows the top 10 condition concepts that showed the highest concept prevalence ratio for the COVID-19 cohort relative to the general cohort and influenza cohort. High ratio of the concepts related to delivery was observed due to unusual spike of delivery events during the pandemic period from March 2020 to August 2020. It is interesting to see the high prevalence ratio of Cerebral infarction in the COVID-19 cohort compared to the influenza cohort, corroborating reports from several studies that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be more likely to cause thrombotic vascular events, including stroke, than other coronavirus and seasonal infectious diseases 18, 19 .

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint

Potential associations between specific concepts of interest can be found by co-occurrence analysis. For example, Table 5 shows the top 10 most frequently co-occurring concepts with Acute lower respiratory tract infection in the COVID-19 cohort. We used non-hierarchical concept cooccurrence in this use case. The concepts associated with SARS-CoV-2 tests (i.e. Disease due to Coronavirus, Radiologic examination, chest; single view, and Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2) showed high cooccurrence prevalence ratio with Acute lower respiratory tract infection. Hydroxychloroquine also showed high co-occurrence prevalence ratio with Acute lower respiratory tract infection.

Symptom prevalence analysis can be used to examine symptom-level characteristics of the cohorts. Figure 7 shows symptom prevalence of the 11 major COVID-19 symptoms for all three cohorts. The COVID-19 cohort showed higher prevalence in dyspnea, fever, and cough symptoms than the other two comparator cohorts, which aligns with the known characteristics and symptoms of COVID-19 patients 20 . . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; 

There are several limitations to this work that should be noted. One of the limitations is that analyses performed in this work can be affected by the factors lying in the data acquisition process (e.g., change of the EHR system, and human biases and errors during entry). For example, coding trends and patterns (i.e., the trend and pattern of frequently used concepts) can be changed by a shift in system. Another limitation is that multiple visits from the same patient can be used to calculate the metrics in the analyses since we used visit-based count instead of patient-based count for the analyses. This could affect the results of the specific concepts appeared in the patients who made unusual visiting pattern.

The EHR data used in this study were obtained from a single site: the CUIMC campus of NewYork-Presbyterian (NYP). Even though NYP is the largest hospital in NYC covering the city and its surrounding area, we admit that performing the analyses based on the EHR data across multiple institutions and nations will be beneficial since multiple sites can diversify the population, improve accuracy, increase power and sensitivity to rare conditions, validate results by comparing across sites, and reduce variance that might exist in specific location. Since the OMOP CDM provides the fundamentals to perform the same analyses on clinical data across different sites, we hope to collaborate with future studies sharing clinical characteristics of COVID-19 patients and to generate a larger, richer, and more robust database that can be leveraged in translational research for COVID-19.

England Journal of Medicine 382, 1708-1720, doi:10.1056/NEJMoa2002032 (2020).

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint Figure 5 . Condition concept prevalence in (a) age and (b) sex sub-cohorts of the COVID-19 cohort. The full COVID-19 cohort refers to the original COVID-19 cohort without stratification.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint Figure 6 . Drug concept prevalence in (a) age and (b) sex sub-cohorts of the COVID-19 cohort. The full COVID-19 cohort indicates original COVID-19 cohort without stratification.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint Figure 7 . Symptom prevalence of 11 major symptoms in COVID-19 patients for all three cohorts.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted November 18, 2020. ; https://doi.org/10.1101/2020.11.17.20232983 doi: medRxiv preprint

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet

In silico studies on therapeutic agents for COVID-19: Drug repurposing approach

Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study

Epidemiological data from the COVID-19 outbreak, real-time case information

A cross-country database of COVID-19 testing

HIT-COVID, a global database tracking public health interventions to COVID-19

A structured open dataset of government interventions in response to COVID-19. medRxiv

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

Columbia Open Health Data, clinical concept prevalence and co-occurrence from electronic health records

Clinical data: sources and types, regulatory constraints, applications

Sex, obesity, diabetes, and exposure to particulate matter among patients with severe asthma: Scientific insights from a comparative analysis of open clinical data sources during a five-day hackathon

First Case of COVID-19 in NYC, First Death Reported in Washington State

Detecting systemic data quality issues in electronic health records

A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data

COVID-19 Daily Counts of Cases, Hospitalizations, and Deaths

Observational study of hydroxychloroquine in hospitalized patients with Covid-19

COVID-19 related stroke in young individuals

Large-vessel stroke as a presenting feature of Covid-19 in the young

Clinical Characteristics of Coronavirus Disease 2019 in China

The code to perform all analyses described in Methods and Usage Notes sections was written in Python 3.5.2 and is publicly available at https://github.com/Jayaos/cohd-covid. The COHD-COVID API is available at http://covid.cohd.io/.ACKNOWLEDGMENT This work was supported by National Library of Medicine grant R01LM012895-03S1 and National Center for Advancing Translational Science grant 1OT2TR003434-01.

The authors have no competing interests to declare.

Junghwan Lee and Casey Ta designed the study and implemented all methods and analyses. Jae Hyun Kim, Cong Liu, and George Hripcsak contributed to evaluate the methods and results of the analyses. Casey Ta and Chunhua Weng co-supervised the study. All authors were involved in developing the ideas and drafting the paper.